Eli Lilly seeks higher NHS drug prices, rebate overhaul to restart UK investment, FT reports

Eli Lilly is reportedly seeking higher drug prices from the NHS and an overhaul of a multi-billion-pound rebate scheme to resume investment in the UK. According to the Financial Times, Patrik Jonsson, president of Eli Lilly’s international businesses, is in talks with UK ministers and is optimistic about reaching an agreement by summer. The discussions also involve innovative pricing plans for anti-obesity drugs, linking payments to patients returning to work, as Lilly claims UK medicine prices have been “far too low for far too long.”

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin